Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

3



INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind M'rabti, Hassan Errihani.

Abstract
Bevacizumab is a recombinant humanized monoclonal antibody targeting the vascular endothelial growth factor; it is actually approved for the treatment of unresectable, locally advanced and metastatic non-small cell lung cancer in association with chemotherapy and as maintenance therapy. Infection risk due to use of bevacizumab is a very rare event. Several cases of aspergillosis in patients treated with monoclonal antibodies have been reported, mostly following treatment with tumor necrosis factor alpha blockers. We present a case of a 60 year-old patient treated for stage IV non-small cell lung cancer, who has been diagnosed with invasive aspergillosis following bevacizumab treatment, and, we postulate that bevacizumab may contribute to this infection.

Key words: Invasive aspergillosis, Bevacizumab



Share this Article


Advertisement
Progress in Orthopedic Science

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
ScopeMed Home
Follow ScopeMed on Twitter
BiblioCAM
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons